Abtherx Inc. has signed a technology license agreement with Rondo Therapeutics with the aim of accelerating Rondo’s pipeline of bispecific antibodies. Rondo aims to advance the field of immuno-oncology, with a focus on treating solid tumors that fail to respond to current therapies.
Repertoire Immune Medicines Inc. has entered into a collaboration and license agreement with Genentech Inc., a member of the Roche Group, to discover and develop innovative T cell-targeted immune medicines to treat an autoimmune disease. Repertoire will use its Decode platform, which maps the immune synapse, to discover novel therapeutic targets.
The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and medical research charity Lifearc have announced a collaboration to develop an affordable and accessible monoclonal antibody (mAb) therapeutic for Crimean-Congo hemorrhagic fever virus (CCHFV).
Elix Inc. has entered into a drug discovery collaboration with Prism Biolab Co. Ltd. to accelerate AI-driven drug discovery for challenging protein-protein interaction targets. The partnership will combine Elix’s AI drug discovery platform with Prism’s proprietary small-molecule peptide mimetic Pepmetics technology for controlling protein-protein interactions.
Boehringer Ingelheim Pharma GmbH & Co KG and Cue Biopharma Inc. have signed a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501, a differentiated B-cell depletion therapy for autoimmune diseases.
Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., has entered into a development and license agreement with Yuva Biosciences Inc. to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions using Yuva’s mitochondrial science-focused platform Mitonova, powered by AI.
Evolveimmune Therapeutics Inc. has announced a translational research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to investigate the expression of a new tumor target – UL binding protein 2 (ULBP2) – in muscle-invasive bladder cancer.
Multiomic Health Ltd. and Alloy Therapeutics Inc. have signed a memorandum of understanding to jointly discover and develop first-in-class renal tissue-targeting drugs. Precision medicines for chronic renal conditions targeted to the kidney tissue of specific patient subpopulations are expected to improve efficacy and safety compared to conventional systemic drugs.
Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Reborna Biosciences Inc. to generate RNA-targeting novel small molecules in the field of the central nervous system.
Navigo Proteins GmbH has established a strategic research collaboration with SCK CEN, the Belgian Nuclear Research Centre, to advance the preclinical development of next-generation radiotheranostics using the Auger-electron emitting radioisotope Terbium (161Tb).
RSS
